Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab
NCT ID: NCT00864838
Last Updated: 2009-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
56 participants
INTERVENTIONAL
2008-06-30
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab
NCT00804921
Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions
NCT05290948
Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
NCT00684853
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage
NCT01091896
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
No interventions assigned to this group
2
Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
Acetazolamide
250 mg 1 hour before intravitreal injection
3
topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
Brimonidine tartarate
1 drop 1 hour before intravitreal injection
4
anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
Anterior chamber paracentesis
Immediately after bevacizumab injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetazolamide
250 mg 1 hour before intravitreal injection
Brimonidine tartarate
1 drop 1 hour before intravitreal injection
Anterior chamber paracentesis
Immediately after bevacizumab injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able and willing to provide informed consent
Exclusion Criteria
* High Myopes (\> 6 spherical diopters)
* High Hyperopes (\> 4 spherical diopters)
* Pulmonary disease
* Renal disease
* Known allergy to any component of the study drug
* Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP
UNKNOWN
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodrigo Jorge, MD
Role: STUDY_CHAIR
University of Sao Paulo
Marco A Bonini-Filho, MD
Role: PRINCIPAL_INVESTIGATOR
University of Sao Paulo
Bianka Y Katayama, MD
Role: STUDY_DIRECTOR
Clinic´s Hospital, Ribeirão Preto Medical School, University of São Paulo
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4429/2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.